Expanded labeling required for ER‐stimulants

The Food and Drug Administration (FDA) is revising the labeling of all extended‐release stimulants indicated to treat attention‐deficit/hyperactivity disorder (ADHD) ‐ including certain formulations of amphetamine and methylphenidate ‐ to warn about the risk of weight loss and other adverse reactions (side effects) in patients younger than 6 years taking these medications.